公开(公告)号：US20190112584A1

公开(公告)日：2019-04-18

申请号：US16104938

申请日：2018-08-19

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.